In addressing the potential limitations of this study, we acknowledge that MCF-7 is a hormone receptor-positive breast cancer cell line and that cisplatin is more commonly associated with triple-negative breast cancer treatment. Here, NR4A1 is linked to triple-negative breast carcinoma.